Theravance Biopharma Investor Relations Material
Latest events
Q3 2024
Theravance Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Theravance Biopharma Inc
Access all reports
Theravance Biopharma Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of respiratory and organ-selective medicines. The company's primary product is YUPELRI (revefenacin), a once-daily nebulized therapy used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Theravance Biopharma is also involved in the development of Ampreloxetine, an investigational norepinephrine reuptake inhibitor, targeting neurogenic orthostatic hypotension, and has collaborations for additional research in respiratory and immunological disorders. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Theravance Biopharma Inc
Q3 2024
Theravance Biopharma Inc
Q2 2024
Theravance Biopharma Inc
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
TBPH
Country
🇺🇸 United States